Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
Ritsuko NakaiSuguru FukuharaAkiko Miyagi MaeshimaSung-Won KimYuta ItoShunsuke HattaTomotaka SuzukiSayako YudaShinichi MakitaWataru MunakataTatsuya SuzukiDai MaruyamaKoji IzutsuPublished in: Clinical case reports (2019)
This is the first case report of alectinib as a bridge to allo-SCT in a patient with ALK-positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.
Keyphrases
- stem cell transplantation
- case report
- poor prognosis
- high dose
- advanced non small cell lung cancer
- long non coding rna
- diffuse large b cell lymphoma
- hodgkin lymphoma
- single cell
- low dose
- cell therapy
- bone marrow
- squamous cell carcinoma
- locally advanced
- lipopolysaccharide induced
- radiation therapy
- inflammatory response
- mesenchymal stem cells